By reducing ERK and AKT pathways as well as the genes associated with the extracellular matrix, pirfenidone not only decreased the migration and proliferation of mesothelioma cells but also altered the mesothelioma tumor microenvironment. The gene discussed is AKT1; the disease is neoplasm.